Skip to main content
PMC home page
Cancer Management and Research logoLink to Cancer Management and Research
. 2019 Mar 28;11:2507–2516. doi: 10.2147/CMAR.S190852

Positive or close margins: reoperation rate and second conservative resection or total mastectomy?

Gilles Houvenaeghel 1,✉, Eric Lambaudie 1, Marie Bannier 2, Sandrine Rua 2, Julien Barrou 2, Mellie Heinemann 1, Max Buttarelli 2, Jeanne Thomassin Piana 3, Monique Cohen 2
PMCID: PMC6445211  PMID: 30992681

Abstract

Introduction

Reoperation after breast-conserving surgery (BCS) could be proposed for positive or close margins. Reoperation type, re-excision or mastectomy, depends on several factors in relation to patient’s and tumor’s characteristics. We have analyzed our breast cancer (BC) database in order to determine second and third attempts for BCS and mastectomy rates, as well as associated factors for type of surgery.

Methods

All patients with BCS between 1995 and 2017 were included. Patient’s characteristics, pathologic results, and treatments were analyzed. Reoperation rate, type of reoperation, second reoperation, and associated factors of reoperation, mastectomy, and third intervention were determined. Three periods were determined: P1–P3.

Results

We analyzed 10,761 patients: 1,161 with ductal carcinoma in situ (DCIS) and 9,600 with invasive BC. The reoperation rate was 41.4% for DCIS and 28.0% for invasive BC. Using multivariate analysis, we identified tumor size >20 mm as being a risk factor for reoperation, whereas age >50 years, P2–3, and some localization decreased reoperation rates. For invasive BC, age >40 years, triple-negative tumors, neoadjuvant chemotherapy, and noncentral tumors decreased reoperation rates and lobular tumor, multifocal tumors, lymphovascular invasion, DCIS component, and Her2-positive tumors increased reoperation rates. For patients requiring reoperation, re-excision was performed in 48.1% (1,523/3,168) and mastectomy was required after first re-excision in 13.46% (205/1,523). For DCIS, mastectomy rates were higher for grade 2 and tumor ≥20 mm. For invasive BC, mastectomy rates were higher for lobular, multifocal, ≥20 mm, Her2-positive tumors and diffuse positive margins and lower for age >50 years and during the last period. Even if interval time between surgery and adjuvant treatments was higher for patients with reoperation, survival rates were not different between patients with and without reoperation.

Conclusion

A decrease in reoperation and mastectomy rates had been reported with several associated factors. A third intervention with mastectomy was required in 13.5% of patients. This information should be done in case of reoperation.

Keywords: breast cancer, conservative surgery, mastectomy, reoperation, margins

Introduction

Reoperation after breast-conserving surgery (BCS) for breast cancer (BC) could be proposed for positive or close margins. Guidelines for reoperation have evolved during the past years: for invasive BC, margins ≥5 mm and then 2 mm and “no ink on tumor” are required, and for ductal carcinoma in situ (DCIS), margins ≥2 mm are usually required.

Reoperation type, re-excision or mastectomy, depends on several factors in relation to patient’s and pathological tumor characteristics, mainly 1) patient’s choice informed of third reoperation risk and no postmastectomy radiotherapy (PMRT) for patients without axillary lymph node macrome-tastases; 2) breast size, tumor size, and tumor localization; and 3) possibility of surgical resection (ie, oncoplasty).

Several studies have reported reoperation rate and type of reoperation after BCS,1–15 but only a few focused on predictive factors determining reoperation type.11,13,16 We have analyzed institutional BC database in order to determine rates and associated factors for reoperation, mastectomy, and third reoperation.

Patients and methods

All patients undergoing BCS in our institution, between January 1995 and December 2017, were included, except those with cT4 and inflammatory BC. A process is in place for institutional BC database to ensure data integrity, accuracy, and completeness. Patient’s and clinical characteristics (cTN stage, age, breast tumor localization), pathologic results (tumor size, Scarff–Bloom–Richardson [SBR] grade, lymphovascular invasion, histological type, tumor focality, phenotype, in situ component, focal [<3 fields at magnification 40], or diffuse positive margins), and treatment (adjuvant chemotherapy [AC] or neoadjuvant chemotherapy [NAC]) were analyzed. Three periods were determined: P1 (1995–2004) with ≥5 mm margins required, P2 (2005–2010) with ≥2 mm margins required, and P3 (after 2010) with negative margins with no ink on tumor.

Reoperation rate and type of reoperation rates (re-excision or mastectomy) and second reoperation after re-excision were analyzed. Factors associated with reoperation, mastectomy, and third intervention were determined. We analyzed interval times between first surgery and reoperation for DCIS, for invasive BC with distinction between patients with or without AC. Overall survival and disease-free survival were compared between patients with and without reoperation.

BCS was undertaken with systematic resection from the subcutaneous layer to major pectoralis muscle and cutaneous resection when tumor was near the skin or when cutaneous retraction was observed. The specimen was pinned on a plate, oriented, and lateral margins inked.

We performed literature review in order to discuss these results.

Statistics

Univariate comparisons were performed using chi-square test. To assess the independent prognostic effect of the variables, a multivariable analysis, using binary logistic regression, was performed. The multivariable model was fitted for those factors that were statistically significant in the univariate analyses. ORs and 95% CIs were estimated for each variable compared to the reference group. Survivals results were compared using the log-rank test. A two-sided P-value of <0.05 was considered as statistically significant. Data analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).

Results

Patients

A total of 10,761 patients were included in the analysis: 1,161 DCIS and 9,600 invasive BC. The characteristics of patients are reported in Table 1.

Table 1.

Reoperation rates for all patients and for DCIS or invasive BC

10,761 patients Total Reoperation χ2 DCIS Reoperation χ2 Invasive Reoperation χ2 Mastectomy χ2
n n % P-value n % P-value n % P-value n (1,404) %a P-value
Age, years ≤40 867 348 40.1 <0.0001 79 54.4 <0.0001 788 38.7 <0.0001 192 63.0 <0.0001
41–50 2,364 851 36.0 259 51.4 2,105 34.1 428 59.6
51–74 6,563 1,799 27.4 770 37.4 5,793 26.1 709 46.9
≥75 967 170 17.6 53 32.1 914 16.7 75 49.0
DCIS – IT and peripheric No (<25%) 7,456 1,859 24.9 <0.0001 6,308 22.0 <0.0001 678 48.9 <0.0001
Yes (≥25%) 3,306 1,309 39.6 3,292 39.5 726 55.8
Focality Unifocal 9,456 2,578 27.3 <0.0001 945 43.5 0.002 8,511 25.5 <0.0001 1,017 46.9 <0.0001
Bifocal 607 308 50.7 55 45.5 552 51.3 185 65.4
Multifocal 251 164 65.3 17 76.5 234 64.5 131 86.8
Unknown 269 110 40.9 96 30.2 173 46.8 68 84.0
Chemotherapy No 5,751 1,357 23.6 <0.0001 4,623 19.3 <0.0001 363 40.8 <0.0001
Adjuvant 4,453 1,711 38.4 4,432 38.3 983 57.9
Neo-adjuvant 525 91 17.3 514 17.3 55 61.8
Phenotype ER+ Her2– 6,159 1,737 28.2 <0.0001 6,062 27.8 <0.0001 761 45.1 <0.0001
ER+ Her2+ 609 219 36.0 577 35.0 107 53.0
ER–Her2+ 284 118 41.5 260 38.8 64 63.4
ER–Her2– 862 201 23.3 846 22.9 106 54.6
ER+ Her2? 1,426 381 26.7 1,336 24.9 242 72.7
ER–Her2? 318 108 34.0 299 32.4 73 75.3
LVI No 8,037 2,241 27.9 <0.0001 6,973 25.6 <0.0001 844 47.3 <0.0001
Yes 2,150 771 35.9 2,146 35.9 479 62.2
Unknown 574 156 27.2 481 27.2 81 61.8
Grade 1 2,969 715 24.1 <0.0001 205 45.4 0.013 2,955 24.0 <0.0001 310 43.8 <0.0001
2 4,145 1,190 28.7 420 40.0 4,125 28.6 626 53.1
3 2,173 678 31.2 401 44.6 2,156 31.1 384 57.2
No grade 16 3 18.8 117 29.1 364 35.2 84 65.6
Global tumor size, mm <20 5,032 833 16.6 <0.0001 468 23.7 <0.0001 4,566 15.8 <0.0001 186 25.8 <0.0001
20–49.9 4,072 1,298 31.9 361 49.9 3,711 30.1 500 44.7
≥50 1,232 946 76.8 200 82.0 782 75.8 677 86.6
Histology DCIS 1,161 481 41.4 <0.0001
Ductal 7,278 1,926 26.5 7,278 26.5 <0.0001 948 49.2 <0.0001
Lobular 1,215 461 37.9 1,215 37.9 289 62.7
Others 1,107 300 27.1 1,107 27.1 167 55.7
Periods 1995–2004 3,407 1,117 32.8 <0.0001 283 55.1 <0.0001 3,124 30.8 <0.0001 672 69.9 <0.0001
2005–2010 2,511 788 31.4 281 50.9 2,230 28.9 369 57.2
>2010 4,843 1,263 26.1 597 30.5 4,246 25.5 363 33.6
Stage cT 0 2,805 766 27.3 <0.0001 2,529 26.3 <0.0001 311 46.8 <0.0001
1 4,003 999 25.0 3,928 24.8 464 47.6
2 2,148 683 31.8 2,114 31.8 415 61.8
3 174 83 47.7 170 47.6 69 85.2
Quadrant Central 589 235 39.9 <0.0001 86 46.5 0.016 503 38.8 <0.0001 110 56.4 <0.0001
Axillary 198 57 28.8 8 12.5 190 29.5 12 21.4
Others 1,040 41.1 8,743 27.1 1,244 52.5
Open in a new tab

Note:

a

Mastectomy rate for invasive BC among patients with reoperation.

Abbreviations: DCIS, ductal carcinoma in situ; BC, breast cancer; Her2?, Her2 unknown; IT, intratumoral; LVI, lymphovascular peritumoral invasion.

Reoperation

Reoperation rate was 29.4% (3,168/10,761: 95% CI 28.5–30.3): 41.4% (481/1,161) and 28.0% (2,687/9,600) for DCIS and invasive BC, respectively. For the total cohort, all factors analyzed were significantly different for reoperation rate in the univariate analysis (Table 1). In the multivariate analysis for DCIS, tumor size ≥20 mm increased reoperation rate and age >50 years, P2–3 periods, and tumor localization (upper superior quadrant and external superior and inferior quadrants) decreased reoperation rates (Table 2). In multivariate analysis for invasive BC, lobular tumor, bifocal or multifocal tumors, presence of lymphovascular peritumoral invasion (LVI), DCIS component, and Her2-positive tumors increased reoperation rates and age >40 years, triple-negative tumors, NAC, and noncentral tumors decreased reoperation rates (Table 3).

Table 2.

Factors associated with reoperation for DCIS BC: multivariate analysis

Reoperation DCIS P-value OR 95% CI
Inferior Superior
Localization Central 1
Axillary 0.122 0.149 0.013 1.662
EIQ 0.052 0.481 0.230 1.008
IIQ 0.922 1.040 0.474 2.283
ESQ 0.036 0.531 0.295 0.958
ISQ 0.092 0.538 0.261 1.106
eEQ 0.572 1.233 0.596 2.554
eInfQ 0.911 0.951 0.393 2.299
eIntQ 0.740 1.150 0.505 2.620
eSupQ 0.056 0.489 0.235 1.018
Age, years ≤40 1
41–50 0.961 0.984 0.522 1.856
51–74 0.010 0.464 0.259 0.831
≥75 0.054 0.425 0.177 1.016
Periods 1995–2004 1 0.920
2005–2010 0.019 0.601 0.392 0.488
>2010 <0.0001 0.337 0.232
Grade 1 1
2 0.347 0.813 0.529 1.251
3 0.209 0.756 0.488 1.170
Unknown 0.028 0.499 0.268 0.929
Size, mm <20 1
20–49.9 <0.0001 3.759 2.697 5.240
≥50 <0.0001 17.76 11.18 28.21
Open in a new tab

Abbreviations: DCIS, ductal carcinoma in situ; BC, breast cancer; EIQ, external inferior quadrants; IIQ, internal inferior quadrant; ESQ, external superior quadrant; ISQ, internal superior quadrant; eEQ, equatorial external quadrant; eInfQ, equatorial inferior quadrant; eIntQ, equatorial internal quadrant; eSupQ, equatorial superior quadrant.

Table 3.

Factors associated with reoperation for invasive BC: multivariate analysis

Reoperation invasive P-value OR 95% CI
Inferior Superior
Localization Central 1
Axillary 0.020 0.618 0.412 0.927
EIQ <0.0001 0.582 0.445 0.762
IIQ <0.0001 0.563 0.413 0.766
ESQ <0.0001 0.527 0.422 0.659
ISQ <0.0001 0.505 0.392 0.651
Inf M fold 0.001 0.087 0.020 0.383
eEQ <0.0001 0.624 0.480 0.813
eInfQ <0.0001 0.431 0.310 0.601
eIntQ <0.0001 0.494 0.352 0.693
eSupQ <0.0001 0.531 0.412 0.684
Age, years ≤40 1
41–50 0.019 0.786 0.642 0.961
51–74 <0.0001 0.558 0.463 0.672
≥75 <0.0001 0.276 0.212 0.359
Periods 1995–2004 1
2005–2010 0.613 0.041 0.891 1.217
>2010 0.863 0.013 0.876 1.170
NAC NAC 0.651
Histology Ductal 0.006 1 0.478 0.886
Lobular <0.0001 0.960 1.678 2.290
Others 0.819 0.979 0.818 1.172
Focality Unifocal 1
Bifocal <0.0001 2.911 2.398 3.534
Multifocal <0.0001 4.717 3.448 6.454
Unknown <0.0001 3.481 2.214 5.472
LVI No 1
Yes 0.004 1.211 1.064 1.378
Unknown 0.025 1.383 1.042 1.836
DCIS component DCIS – IT/peripheric <0.0001 2.490 2.237 2.772
Grade 1 1
2 0.954 0.004 0.884 1.140
3 0.766 1.026 0.867 1.213
Unknown 0.474 1.152 0.782 1.698
Phenotype ER+ Her2–
ER+ Her2+ 0.037 1.252 1.014 1.545
ER– Her2+ 0.001 1.692 1.235 2.317
ER– Her2– 0.041 0.802 0.649 0.991
ER+ Her2? <0.0001 0.608 0.504 0.733
ER– Her2? 0.302 0.848 0.619 1.160
Size invasive, mm <20 1
20–49.9 <0.0001 1.434 1.280 1.607
≥50 <0.0001 9.324 7.389 11.766
Open in a new tab

Abbreviations: BC, breast cancer; EIQ, external inferior quadrant; IIQ, internal inferior quadrant; ESQ, external superior quadrant; ISQ, internal superior quadrant; Inf M fold, inferior mammary fold; eEQ, equatorial external quadrant; eInfQ, equatorial inferior quadrant; eIntQ, equatorial internal quadrant; eSupQ, equatorial superior quadrant; NAC, neoadjuvant chemotherapy; LVI, lymphovascular peritumoral invasion; DCIS, ductal carcinoma in situ; IT, intratumoral.

Reoperation type

For patients, who needed reoperation, a mastectomy was performed at first reoperation in 51.9% (1,645/3,168; 241/481: 50.1% for DCIS and 1,404/2,687: 52.2% for invasive BC) and mastectomy was required after first reoperation with re-excision in 13.46% (205/1,523: 35 for DCIS and 170 for invasive BC) with a total mastectomy rate of 58.4% (1,850/3,168; 276/481: 57.4% for DCIS and 1,574/2,687: 58.6% for invasive BC). For DCIS, the mastectomy rate was higher for grade 2 tumors and tumor sizes ≥20 mm (Table 4). For invasive BC, the mastectomy rate was higher for lobular tumors, bifocal or multifocal tumors, tumor sizes ≥20 mm, Her2-positive tumors, and diffuse positive margins and lower for age >50 years and patients treated during the last period (Table 5).

Table 4.

Factors associated with reoperation with mastectomy for DCIS BC: multivariate analysis

Mastectomy reoperation DCIS P-value OR 95% CI
Inferior Superior
Localization Central 1
All others NS
Age, years ≤40 1
41–50 0.854 0.920 0.380 2.228
Periods 1995–2004 1
2005–2010 0.740 1.047 0.381 1.986
>2010 0.877 0.648 0.586 1.870
51–74 0.129 0.870 0.369 1.135
≥75 0.939 0.947 0.230 3.896
Grade 1 1
2 0.048 1.931 1.005 3.712
3 0.980 1.008 0.527 1.928
Unknown 0.202 1.966 0.695 5.557
Size, mm <20 1
20–49.9 0.007 2.389 1.265 4.510
≥50 <0.0001 18.02 9.189 35.34
Open in a new tab

Abbreviation: DCIS, ductal carcinoma in situ; BC, breast cancer; NS, not significant.

Table 5.

Factors associated with reoperation with mastectomy for invasive BC: multivariate analysis

Re-excision vs mastectomy Invasive P-value OR 95% CI
Inferior Superior
Histology Ductal 1
Lobular <0.0001 1.820 1.369 2.418
Others 0.348 1.175 0.839 1.646
LVI No 1
Yes 0.066 1.247 0.985 1.578
Periods 1995–2004 1
2005–2010 0.552 0.917 0.688 1.221
>2010 <0.0001 0.429 0.328 0.562
Focality Unifocal 1
Bifocal <0.0001 2.955 2.161 4.041
Multifocal <0.0001 9.334 5.497 15.85
Grade 1 1
2 0.024 1.336 1.039 1.719
3 0.039 1.393 1.016 1.909
DCIS component DCIS – IT and peripheric 0.393 0.911 0.736 1.128
Positive margins Focal 1
Diffuse <0.0001 2.508 1.880 3.346
Age, years ≤40 1
41–50 0.835 0.963 0.673 1.377
51–74 0.002 0.602 0.433 0.836
≥75 0.309 0.768 0.462 1.276
Global size, mm <20 1
20–49.9 <0.0001 2.372 1.856 3.032
≥50 <0.0001 18.16 13.32 24.75
Phenotype ER+ Her2– 1
ER+ Her2+ 0.048 1.453 1.003 2.105
ER– Her2+ 0.007 2.085 1.228 3.540
ER– Her2– 0.20 1.294 0.873 1.919
Open in a new tab

Abbreviations: BC, breast cancer; LVI, lymphovascular peritumoral invasion; DCIS, ductal carcinoma in situ; IT, intratumoral.

Among patients with re-excision, factors associated with reoperation with mastectomy in binary logistic regression were tumor size ≥20 mm; multifocal tumors, which increased mastectomy rates; and age >50 years, which decreased mastectomy rates (Table 6).

Table 6.

Factors associated with third operation with mastectomy: multivariate analysis

Factors of mastectomy third operation Among re-excision P-value OR 95% CI
Inferior Superior
Histology DCIS 1
Ductal 0.937 1.033 0.463 2.305
Lobular 0.622 1.244 0.523 2.960
Others 0.903 1.060 0.414 2.717
Global size, mm <20 1
20–49.9 <0.0001 2.374 1.463 3.852
≥50 <0.0001 16.72 9.841 28.42
Focality Unifocal 1
Bifocal 0.205 1.471 0.809 2.675
Multifocal 0.017 3.120 1.225 7.948
LVI No 1
Yes 0.532 0.868 0.556 1.355
DCIS component DCIS – IT and peripheric 0.539 0.884 0.596 1.311
Phenotype ER+ Her2– 1
ER+ Her2+ 0.175 1.503 0.834 2.709
ER– Her2+ 0.524 1.338 0.546 3.277
ER– Her2– 0.787 0.896 0.403 1.989
Age, years ≤40 1
41–50 0.811 1.073 0.601 1.916
51–74 0.005 0.448 0.256 0.784
≥75 0.033 0.281 0.087 0.902
Open in a new tab

Abbreviations: DCIS, ductal carcinoma in situ; LVI, lymphovascular peritumoral invasion; IT, intratumoral.

Interval time

The median interval time between first surgery and reoperation for DCIS was 35 days (mean: 44.58, 95% CI 41.3–47.8) and 78 days for patients with a second reoperation (mean 90.9, 95% CI 75.9–105.8). Median interval time between first operation and radiotherapy for patients with DCIS was 55 days (mean 63, 95% CI 60.4–65.6) and for patients with re-excision (n = 238) or no reoperation (n = 562), it was 77 days (mean 89.8, 95% CI 83.4–96.1) or 47 days (mean 51.7, 95% CI 49.8–53.6), respectively.

The median interval time between first surgery and reoperation (first reoperation) for invasive BC was 29 days (mean 47.7, 95% CI 39.6–55.8) and 123 days for patients with a second reoperation (mean: 133, 95% CI 121–145). When AC was administered, reoperation was performed before or after chemotherapy. The median interval time between first surgery and reoperation for invasive BC was 28 days (mean 33, 95% CI 31.8–34.1) for patients without any treatment before reoperation (AC after reoperation or patients with previous NAC or patients without AC before reoperation) and 173.5 days (mean 179, 95% CI 174–184) for patients with AC before reoperation.

The median time interval between first operation and radiotherapy for patients with invasive BC without AC was 73 days (mean 142 days, 95% CI 14–270) and 46 days for patients with or without reoperation (mean 47.3 days, 95% CI 46–48), respectively.

For patients with invasive BC and AC, the median interval time between first operation and AC was 42 days (mean 47.3 days, 95% CI 45.8–48.9) and 34 days (mean 36.9 days, 95% CI 36–38) for patients with reoperation and without reoperation, respectively, and the median interval time between first operation and radiotherapy was 188 days (mean 186.5 days, 95% CI 184–189) and 167 days (mean 158 days, 95% CI 156–160) for patients with reoperation and without reoperation, respectively.

Survival

The median follow-up was 53.2 months (95% CI 56.7–89.0 months). Overall survival and disease-free survival were not different between patients with and without reoperation (log-rank test: 0.393 and 0.963 for invasive BC and 0.212 and 0.231 for DCIS).

Discussion

In our study, the reoperation rate for DCIS was high (41.4%) but lower during the two last periods (decrease of 24.6%), and higher mastectomy rates (49.9%) were reported for tumors ≥20 and <50 mm. These results are concordant with literature results.17 Higher reoperation rates were also observed in the literature survey results for lobular carcinomas. The reoperation rate for invasive BC was 28.0%, higher for young patients, triple-negative and Her2-positive tumors, lobular carcinomas, and multifocal tumors and lesser after NAC. Higher mastectomy rates for reoperation were also observed in our study mainly for these same factors. However, NAC was proposed for patients who need mastectomy before NAC or for patients with aggressive tumors (ie, SBR grade 3, Her2-positive, triple negative) and axillary involvement at ultrasonography and percutaneous biopsy.

In literature review, the mean reoperation rate (re-excision or mastectomy) was 27.49% (95% CI 27.4–27.6, range: 10.2%–34%) among 402,357 patients with BC (DCIS or invasive) operation.1–15

Re-excision rates for BCS are extremely variable across the literature. This is mainly due to no clear consensus regarding the definition of a negative margin, different preoperative and intraoperative tumor localizing methods, differences in intraoperative imaging techniques, specimen inking by surgeons or pathologists, the use of shave margins, tumor vs lumpectomy size, oncoplastic resections, volume of breast surgery per year by surgeons, and surgeon threshold to offer re-excision vs mastectomy for positive margins.13,18,19

When analysis of reoperation rates was performed according to three periods of treatment, we observed a decrease in reoperation rates among successive periods from 28.96% (4,594/15,861, 95% CI 28.3–29.7) to 30.66% (79,708/259,943, 95% CI 30.5–30.8) and 21.34% (20,016/93,779, 95% CI 21.1–21.6).1,3–7,9–15 In the study reported by Morrow et al,9 surgery after initial lumpectomy declined by 16% (P < 0.001) from 2013 to 2015.

Reoperation rates were different for invasive BC and DCIS in literature reviews: 26.56% (86,797/326,828, 95% CI 26.4–26.7, range: 10.4–30.5) and 33.1% (21,594/65,261, 95% CI 32.7–33.5, range: 8.97–41.4),1–3,7,14 respectively. However, reoperation rates differed between histological types of invasive BC: 26.98% for ductal invasive BC, 40.6% for lobular invasive BC, and 21.83% for others invasive histological types.2

For DCIS, there was no statistically significant difference in locoregional recurrence (LRR) for patients with margins <2 versus ≥2 mm who received radiotherapy (10-year LRR 4.8% vs 3.3%, respectively; P = 0.72).20 One other large study evaluating the relationship between margin width and recurrence did not identify a significant association of recurrence with margin width of ≤2 mm compared with larger margins for patients receiving radiotherapy.21 However, Morrow et al22 reported in 2016 that 2 mm margin minimizes the risk of ipsilateral breast tumor recurrence (IBTR) compared with smaller negative margins, using a meta-analysis of margin width and IBTR from a systematic review.

A conservative reoperation was done is ~50% of patients with DCIS or ductal invasive BC and lesser for lobular invasive BC (~30%) with a decrease in mastectomy rates among successive periods analyzed. In our study, interval times between first surgery and adjuvant treatments increased for patients who needed reoperation but without significant impact on survival.

A third intervention for mastectomy had been reported in three studies,1,3,6 and in our study: mastectomy rate after re-excision was 13.54% (1,059/7,818, 95% CI 12.8–14.3). Mastectomy rates among 108,446 patients with reoperation in the literature review were 40.77% (95% CI 40.5–41.1, range: 10.7–62.1) and 55.4% (95% CI 54.6–56.2) for studies with analysis of a third intervention for mastectomy (8,309/14,998).1,3,6

When analysis of mastectomy rates was performed according to the three periods of treatment (DCIS and invasive), we observed a decrease in mastectomy rates among successive periods from 59.62% (2,739/4,594, 95% CI 58.2–61.0) to 48.8% (2,532/5,191, 95% CI 47.4–50.2) and 36.81% (6,892/17,903, 95% CI 36.1–37.5).3,4,6,7,9,11 In the study reported by Wilke et al,5 the mastectomy rate was 37.9% for patients operated between 2004 and 2010.

Mastectomy rates were different according to histological types of tumor: 49.7% (1,960/3,942, 95% CI 48.1–51.3) for DCIS,1,4–6,8,11,13,14 50.9% (9,446/18,566, 95% CI 50.2–51.6) for invasive BC, 55.7% (95% CI 54.5–56.9) for ductal invasive BC, 70.5% (95% CI 68.3–72.7) for lobular invasive BC, and 60.9% (95% CI 57.8–64.0) for other invasive histological types.2

After initial oncoplastic surgery, close or positive margins was reported in 12.3% (342/2,772, 95% CI 11.1–13.5) of patients in a meta-analysis reported in 2014,23 and the mastectomy rate for reoperation after initial oncoplastic resection was high: 64% in Clough et al’s24 study and 61.3% in Losken et al23 meta-analysis.

Interval time between surgery or first surgery for patients who need reoperation and adjuvant treatment: even if interval time was higher for patients with reoperation, we did not observe impact on survival results between patients with or without reoperation.

Conclusion

A decrease of reoperation rate and mastectomy rate in future years is probably in relation with negative margin resection without several mm of margin, more accurate preoperative radiologic analysis, particularly for lobular and multifocal tumors; more oncoplastic resections; and more NAC. A third intervention with mastectomy was required in about 13%–14% of patients. Information about risk of a third intervention should be given to patients who require reoperation.

Even if interval time between surgery and adjuvant treatments was higher for patients with reoperation, survival results were not different between patients with and without reoperation.

Ethics approval and consent to participate

This work was approved by our institutional review board (IPC – Comité d’Orientation Stratégique). All procedures performed in this study involving human participants were done in accordance with the French ethical standards and 2008 Declaration of Helsinki. All included patients provided written informed consent before surgery, including for the use of their data for research.

Footnotes

Author contributions

All authors contributed equally to this study. All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.van Leeuwen MT, Falster MO, Vajdic CM, et al. Reoperation after breast-conserving surgery for cancer in Australia: statewide cohort study of linked hospital data. BMJ Open. 2018;8(4):e020858. doi: 10.1136/bmjopen-2017-020858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Vos EL, Siesling S, Baaijens MHA, et al. Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. Breast Cancer Res Treat. 2017;164(1):157–167. doi: 10.1007/s10549-017-4232-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fisher S, Yasui Y, Dabbs K, Winget M. Re-excision and survival following breast conserving surgery in early stage breast cancer patients: a population-based study. BMC Health Serv Res. 2018;18(1):94. doi: 10.1186/s12913-018-2882-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Jeevan R, Cromwell DA, Trivella M, et al. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ. 2012;345:e4505. doi: 10.1136/bmj.e4505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wilke LG, Czechura T, Wang C, et al. Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma: a report from the National Cancer data base, 2004–2010. JAMA Surg. 2014;149(12):1296–1305. doi: 10.1001/jamasurg.2014.926. [DOI] [PubMed] [Google Scholar]
  • 6.Langhans L, Jensen MB, Talman MM, Vejborg I, Kroman N, Tvedskov TF. Reoperation rates in ductal carcinoma in situ vs invasive breast cancer after wire-guided breast-conserving surgery. JAMA Surg. 2017;152(4):378. doi: 10.1001/jamasurg.2016.4751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Landercasper J, Whitacre E, Degnim AC, Al-Hamadani M. Reasons for re-excision after lumpectomy for breast cancer: insight from the American Society of Breast Surgeons Mastery(SM) database. Ann Surg Oncol. 2014;21(10):3185–3191. doi: 10.1245/s10434-014-3905-1. [DOI] [PubMed] [Google Scholar]
  • 8.Romics L, Macaskill EJ, Fernandez T, et al. A population-based audit of surgical practice and outcomes of oncoplastic breast conservations in Scotland – An analysis of 589 patients. Eur J Surg Oncol. 2018;44(7):939–944. doi: 10.1016/j.ejso.2018.04.004. [DOI] [PubMed] [Google Scholar]
  • 9.Morrow M, Abrahamse P, Katz SJ. Trend analysis on reoperation after lumpectomy for breast cancer-reply. JAMA Oncol. 2018;4(5):747. doi: 10.1001/jamaoncol.2017.5261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Morrow M, Jagsi R, Alderman AK, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302(14):1551–1556. doi: 10.1001/jama.2009.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Philpott A, Wong J, Elder K, Gorelik A, Mann GB, Skandarajah A. Factors influencing reoperation following breast-conserving surgery. ANZ J Surg. 2018;88(9):922–927. doi: 10.1111/ans.14467. [DOI] [PubMed] [Google Scholar]
  • 12.Findlay-Shirras LJ, Outbih O, Muzyka CN, Galloway K, Hebbard PC, Nashed M. Predictors of residual disease after breast conservation surgery. Ann Surg Oncol. 2018;25(7):1936–1942. doi: 10.1245/s10434-018-6454-1. [DOI] [PubMed] [Google Scholar]
  • 13.Hughes L, Hamm J, Mcgahan C, Baliski C. Surgeon volume, patient age, and tumor-related factors influence the need for Re-Excision after breast-conserving surgery. Ann Surg Oncol. 2016;23(Suppl 5):656–664. doi: 10.1245/s10434-016-5602-8. [DOI] [PubMed] [Google Scholar]
  • 14.Heelan Gladden AA, Sams S, Gleisner A, et al. Re-excision rates after breast conserving surgery following the 2014 SSO-ASTRO guidelines. Am J Surg. 2017;214(6):1104–1109. doi: 10.1016/j.amjsurg.2017.08.023. [DOI] [PubMed] [Google Scholar]
  • 15.Tang SS, Kaptanis S, Haddow JB, et al. Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland. Eur J Cancer. 2017;84:315–324. doi: 10.1016/j.ejca.2017.07.032. [DOI] [PubMed] [Google Scholar]
  • 16.Amabile MI, Mazouni C, Guimond C, et al. Factors predictive of re-excision after oncoplastic breast-conserving surgery. Anticancer Res. 2015;35(7):4229–4234. [PubMed] [Google Scholar]
  • 17.Houvenaeghel G, Lambaudie E, Bannier M, et al. Re-operation and mastectomy rates after breast conservative surgery for positive or close margins: a review. Clin Surg. 2018;3:2149. [Google Scholar]
  • 18.Chagpar AB, Killelea BK, Tsangaris TN, et al. A randomized, controlled trial of cavity shave margins in breast cancer. N Engl J Med. 2015;373(6):503–510. doi: 10.1056/NEJMoa1504473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Pleijhuis RG, Graafland M, de Vries J, Bart J, de Jong JS, van Dam GM. Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol. 2009;16(10):2717–2730. doi: 10.1245/s10434-009-0609-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kuerer HM, Smith BD, Chavez-Macgregor M, et al. DCIS margins and breast conservation: MD Anderson cancer center multidisciplinary practice guidelines and outcomes. J Cancer. 2017;8(14):2653–2662. doi: 10.7150/jca.20871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;262:623–631. doi: 10.1097/SLA.0000000000001454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Morrow M, van Zee KJ, Solin LJ, et al. Society of surgical oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Ann Surg Oncol. 2016;23(12):3801–3810. doi: 10.1245/s10434-016-5449-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Losken A, Styblo TM, Carlson GW, Jones GE, Amerson BJ. Management algorithm and outcome evaluation of partial mastectomy defects treated using reduction or mastopexy techniques. Ann Plast Surg. 2007;59(3):235–242. doi: 10.1097/SAP.0b013e31802ec6d1. [DOI] [PubMed] [Google Scholar]
  • 24.Clough KB, van La Parra RFD, Thygesen HH, et al. Long-term results after oncoplastic surgery for breast cancer: a 10-year follow-up. Ann Surg. 2018;268(1):165–171. doi: 10.1097/SLA.0000000000002255. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Management and Research are provided here courtesy of Dove Press

RESOURCES